|
Post by actcrazy on Mar 18, 2017 3:51:29 GMT
I also added today...doubled my position...now averaged at 21.10 GLTA here!
|
|
|
Post by iamaverb on Mar 23, 2017 3:29:04 GMT
CEO Katrine Bosley of Editas discusses the terms of the Allergan deal, and it turns out it may be a BIG deal. Editas deal may be worth a billionAs a side note, I hope the company reports tomorrow the entire 4.6million shares were sold and delivered by the stated date of 03.22.2017. If not, there may be more blood.
|
|
|
Post by stargazer on Mar 23, 2017 16:26:35 GMT
IAV Any opinion on NTLA? It has the Cas9 patent for the EU and partnerships with REGN and others. Also lots of cash on its books - around $8.5/share. In the meantime picked up a few more edit today
|
|
|
Post by actcrazy on Mar 24, 2017 2:55:23 GMT
NTLA closed @ 13.19 US today. Edit gave up 8% why? Unknown to me at this time.
|
|
|
Post by iamaverb on Mar 24, 2017 12:39:08 GMT
CEO Katrine Bosley of Editas discusses the terms of the Allergan deal, and it turns out it may be a BIG deal. Editas deal may be worth a billionAs a side note, I hope the company reports tomorrow the entire 4.6million shares were sold and delivered by the stated date of 03.22.2017. If not, there may be more blood.Since EDIT did not announce on the 22nd they had closed the share offering or delivered all 4 million shares nor the additional 600K shares, I have to believe that the interest in these additional shares was just not as expected. I have thoughts of the stem cell company Ocata and their share offering they eventually had to pull for lack of interest running through my head, though in this case a day after Editas announced the share offering, they released a second amended 8-K that stated JP and Cowan had agreed to purchase all of the shares at a discount. Perhaps the initial interest was weaker than expected, and JP/Cowan felt obligated to buy the shares and sell them as they could. If so, they might have hurt themselves at this price level. The CEO of Editas had to come out in an interview with the additional financial information of the Allergan deal perhaps to shore up support to help get the shares sold, and it surprises me that the shares dropped so much yesterday. A report in February showed short interest was up 28%, but I figured the Allergan deal would have muted those effects.
|
|
|
Post by iamaverb on Mar 24, 2017 13:57:44 GMT
IAV Any opinion on NTLA? It has the Cas9 patent for the EU and partnerships with REGN and others. Also lots of cash on its books - around $8.5/share. In the meantime picked up a few more edit today The lack of volume in comparison to EDIT makes me cautious with NTLA and to a greater extent, CRSP. Shortly after the patent decision I liquidated my positions in these two stocks and concentrated my investment in EDIT. With the outcome of the patent interference case, I have to believe EDIT will appear to be the sure bet and will receive more collaboration interest from big pharma.
|
|
|
Post by iamaverb on Mar 28, 2017 19:40:37 GMT
|
|
|
Post by iamaverb on Mar 29, 2017 15:16:24 GMT
I'm surprised by the relative strength in the price of EDIT since it is apparent they haven't closed out the offering after 10 days. I anticipate the price will begin a slow but steady rise into the 30's once the offering is closed. And speaking of which....show me the money. It appears the underwriters and the company overestimated the demand for the shares. Yesterdays rise in the price level was a breakeven price so I am hopeful many of the shares were consumed in the market. The company may have delivered the 800K shares to The Broad for payment of the patent rights so those additional shares may have hit the market at the same time.
|
|
|
Post by iamaverb on May 14, 2017 23:59:49 GMT
Over the years some of us on this forum have followed the quest of repairing the photoreceptors in the eyes as a means to curing many forms of blindness. Early pioneers such as Dr. Robert Lanza used hESC / human embryonic stem cells with good results, but faced steep regulatory hurdles. Congratulations and God Speed to Editas and Allergan for pioneering the use of edited genes as a potential cure. Editas reports earnings after close on Monday. Editas shows proof of concept for repairing photoreceptors
|
|
|
Post by iamaverb on May 16, 2017 15:36:13 GMT
Per the conference call this evening, the filing of the Editas IND (investigational new drug) application with the FDA is delayed until mid 2018 because of a 3rd party contractor manufacturing problem that has since been cured. The market may not look kindly on this. On the bright side to delay will allow Allergan to provide their extensive expertise in the early development for the LCA10 and other developmental programs.
|
|
|
Post by mattyj7183 on Jun 22, 2017 12:52:30 GMT
|
|
|
Post by iamaverb on Jun 22, 2017 14:25:30 GMT
Good catch. This is somewhat common and Editas filed at least one of these on March 1st., which was just days before announcing the departure of their COO, and just a few weeks before announcing the Allergan deal. Can another deal be forthcoming? Yesterday and today Editas management has held two meetings with JMP Securities in San Fran and then in Chicago. Editas Medicine, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on May 15, 2017. Based on representations by Editas Medicine, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified: Exhibit 10.1 through May 15, 2020 For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:
|
|
|
Post by selluwud on Jun 22, 2017 14:52:01 GMT
Good catch. This is somewhat common and Editas filed at least one of these on March 1st., which was just days before announcing the departure of their COO, and just a few weeks before announcing the Allergan deal. Can another deal be forthcoming? Yesterday and today Editas management has held two meetings with JMP Securities in San Fran and then in Chicago. Editas Medicine, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on May 15, 2017. Based on representations by Editas Medicine, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified: Exhibit 10.1 through May 15, 2020 For the Commission, by the Division of Corporation Finance, pursuant to delegated authority: The Allergen deal was announced (3/14) 2 weeks after the CTO was filed and the pps hit the 52 week high.
|
|
|
Post by iamaverb on Jun 23, 2017 20:44:43 GMT
Editas just traded 2 million shares in the closing seconds of trading Friday, and traded another 1,238,000 shares in the after market, for a total that is 5x's the average daily volume. I own calls in Juno and it has been on a tear lately. I am just speculating but today JUNO traded double the daily average and added 1 million shares after market. Editas does have a collaboration with JUNO, but news has been nonexistent. Any good news next week should send those who are shorting the stock for cover. I look forward to Monday and a good cup of Joe.
|
|
|
Post by stargazer on Jul 29, 2017 20:46:30 GMT
|
|
|
Post by selluwud on Jul 30, 2017 14:34:50 GMT
I was here but moved out and into RDHL. I may come back once they have moved further along with trial development and approvals.
|
|
|
Post by jerojuujarvi on Aug 21, 2017 5:35:35 GMT
|
|
|
Post by iamaverb on Nov 11, 2017 20:18:57 GMT
A few updates on Editas. The company presented with their partner JUNO regarding their CarT program at the SITC conference yesterday and their share prices climbed 7.5% and 5.5% respectively. They present again on another program on the 8th of December at the upcoming ASH conference. UC Berkeley presents their brief to the appeals court by November 25th for the interference case, and then oral arguments in Q1 of 2018. Editas is also on track to submit their IND to the FDA for their LCA10 CRISPR gene editing blindness cure in partnership with Allergan. The interference case should be settled by mid 2018, since the appeal is solely based on the legal aspect of the USPTO decision and not on the science. I had sold about a third of Editas and put into O&G a while back, as I believe both can give me good returns.
|
|
|
Post by iamaverb on Nov 22, 2017 23:01:10 GMT
Nice 6% to 9% moves in the three CRISPR stocks today with good volume with a new 18 month high in EDIT. Might be a short squeeze occurring.
|
|
|
Post by iamaverb on Nov 27, 2017 4:10:41 GMT
UCB presented their appellate brief to the Federal Appeals Court late Wednesday, putting in motion the timing for the upcoming oral arguments. This will be the the most important patent trial of our generation
|
|